Att B - Task Deliverables Table.xlsx
XLSX spreadsheet 22 KB Posted
- Solicitation number
- RFP_75D301-20-R-68127
About this file
This document outlines requirements for a federal contract to provide laboratory testing services for the CDC Multistate Assessment of SARS-CoV-2 Seroprevalence (MASS) Study. The solicitation number is RFP_75D301-20-R-68127 and is seeking proposals by September 7, 2020 at 5PM EST to begin services on October 12, 2020. The contract will be awarded full and open with no set aside. Laboratory testing services will include ELISA, microneutralization, and quantitative IgG assays for COVID-19 specimens as well as data reporting every two weeks. Offerors must submit questions by August 24, 2020 and be responsive to CDC requests for status updates, meetings, and inquiries given the importance of addressing the public health emergency. The contract will be awarded by the Department of Health and Human Services Centers for Disease Control and Prevention Office of Acquisition Services.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| Att D - Question and Answer Template.xlsx | XLSX spreadsheet | |
| Att C - Pricing Table.xlsx | XLSX spreadsheet | |
| Att A - Offeror Capabilities and Specimens.xlsx | XLSX spreadsheet | |
| RFP 75D301-20-R-68127.pdf |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Sheet1
| Task Deliverables | Frequency | Brief Description | Critical Elements | |
| Task Area 1: Request for COVID-19 IgG and IgM ELISA Testing | ||||
| 1.2 | Specimen Testing | begins within 48 hours of task area 1.1 and continuous thereafter | CDC anticipates a testing rate of 51,000 samples every two weeks, possibly spread among multiple offerors. | Testing will include CLIA-approved and/or EUA-approved ELISA, COVID-19 IgG and IgM serological assays. Tests (with specific test names) will be selected from offeror(s) proposals during the task order award. The required sample matrix and sample volume should be specified for each offered test name. |
Quantitative assays will receive priority.
If qualitative testing is selected under task area 1, the offeror(s) will need to be able to ship any CDC-selected seropositive specimens to CDC-designated facilities for reflexive testing described under task areas 2 and 3. A subset of seronegative specimens may also be selected for reflexive testing
1.3 Draft Data Report and Review Meeting 1 and 2 weeks post award Offeror(s) will provide a sample draft data report electronically to the CDC Project Officer at vsm8@cdc.gov one week post award and schedule a meeting for review two weeks post award. Data reports will include a 1-2 page cover letter stating a summary of findings, the CDC contract number, the tests run (with specific test names that are traceable to the task order test protocols offered), the total number of specimens tested, the total number of seropositive specimens identified, any items of note such as trends, corrective actions, or other anomalies, and be signed by the laboratory signatory.
Data reports will include a locked Excel file, an unlocked Excel file, and a .CSV file type.
The data reports will include at a minimum: the test run date, the test name, any lab comments of note, test result(s), the units of measurement, test limits of detection, the remaining sample volume available for reflexive testing, and a column indicating seropositivity. Based on availability of metadata, the report will also include at a sample level: Patient age (years), Gender, Race and ethnicity (if available), Geographic location (residence zip code), Provider 5-digit zip code if residence not available, ICD10 diagnosis associated with the original laboratory test, Results (including collection date) of any previous COVID-19 testing on the same patient, Specimen collection date, Information on if the specimen came from an outpatient or inpatient facility (if available), Unique patient identifier to allow for deduplication of sample results from the same patient.
| 1.4 | Data Reporting | every 2 weeks | Offeror(s) will provide a data report electronically to the CDC Project Officer at vsm8@cdc.gov for every two weeks of testing post award. |
| 1.6 | Specimen Shipping (if applicable) | begins 1.5 mos post-award and then every 2 weeks | If needed, offeror(s) must be able to ship specimens to other CDC-designated facilities in the United States. |
CDC anticipates approximately 29,000 specimens for reflexive testing. If the residual specimens selected under task area 1.1 exceeds an offeror's specimen two-week testing capacity under task area 1.2, the offeror will ship the CDC selected residual specimens to another testing facility designated by CDC.
Additionally, offeror(s) with any COVID-19 seropositive specimens identified from task area 1.2 and selected by CDC for reflexive testing in task areas 2.1 and 3.1 must be able to ship those samples to a CDC designated facility for reflexive testing, if different than the facility where specimens were tested under task area 1.2. A small subset of seronegative specimens may also be selected for reflexive testing
1.7 Draft Final Report and Review Meeting once four weeks prior to end of performance period Offeror(s) will submit a sample draft of the final report for the task order four weeks prior to the end of the award performance period to the CDC Project Officer at vsm8@cdc.gov The final report will include at a minimum: a summary of work performed (total number of specimens analyzed, total number of specimens seropositive, and those totals broken out by each two-week surveillance period).
The report appendices of the report should include at a minimum: each data report, shipping manifests (if applicable), test protocols, meeting agendas, and invoices.
1.8 Final Report once after all testing has been completed and no later than four weeks after the testing period has concluded Offeror(s) will submit a final report for the task order at the end of the award performance period to the CDC Project Officer at vsm8@cdc.gov
A four week lead time beyond the period of testing will be allowed for final report submission so that data collected at the end of the testing period can be incorporated in the final report.
| N/A | Invoicing | monthly | Offeror(s) will invoice their work under this contract monthly by submitting their invoices electronically to the CDC at fmoapinv@cdc.gov and copying the CDC Project Officer at vsm8@cdc.gov | Note: If offeror(s) are performing work under multiple task areas during one month, they may combine multiple task areas in one invoice as long as the work performed is distinguishable between task areas. |
| N/A | Status Updates and Meetings | upon award, bi-weekly, and upon request | Offeror(s) will update CDC regularly and respond to inquiries as requested. | Offeror(s) will be responsive to CDC requests for status updates and questions, especially given the importance of this work in addressing a public health emergency. |
Offeror(s) will include the CDC contract number in the body of all emails, reports, and meeting agendas for future tracking purposes.
| Task Area 2: Request for Reflexive COVID-19 Microneutralization Assay Testing | ||||
| 2.1 | Reflexive Specimen Testing | begins 1.5 mos post-award | CDC estimates approximately 1,600 specimens every two weeks requiring microneutralization testing, possibly spread among multiple offerors. | This testing will include microneutralization assays for seropositive specimens identified in task area 1.1. Tests (with specific test names) will be selected from offeror(s) proposals during the task order award. The required sample matrix and sample volume should be specified for each offered test name. |
| 2.2 | Draft Data Report | 1 and 2 weeks after reflexive testing begins | Offeror(s) will provide a sample draft data report electronically to the CDC Project Officer at vsm8@cdc.gov one week post award and schedule a meeting for review two weeks post award. | Data reports will include a 1-2 page cover letter stating a summary of findings, the CDC contract number, the tests run (with specific test names that are traceable to the task order test protocols offered), the total number of specimens tested, the total number of seropositive specimens identified, any items of note such as trends, corrective actions, or other anomalies, and be signed by the laboratory signatory. |
Data reports will include a locked Excel file, an unlocked Excel file, and a .CSV file type.
In addition to the specimen information included in Attachment A, the data reports will include at a minimum: the test run date, the test name, any lab comments of note, test result(s), the units of measurement, test limits of detection, the remaining sample volume available for reflexive testing, and a column indicating seropositivity.
| 2.3 | Data Reporting | every 2 weeks after reflexive testing begins | Offeror(s) will provide a data report electronically to the CDC Project Officer at vsm8@cdc.gov for every two weeks of testing post award. | |
| 2.4 | Draft Final Report and Review Meeting | once four weeks prior to end of performance period | Offeror(s) will submit a sample draft of the final report for the task order four weeks prior to the end of the award performance period to the CDC Project Officer at vsm8@cdc.gov | The final report will include at a minimum: a summary of work performed (total number of specimens analyzed, total number of specimens seropositive, and those totals broken out by each two-week surveillance period). |
The report appendices of the report should include at a minimum: each data report, shipping manifests (if applicable), test protocols, meeting agendas, and invoices.
2.5 Final Report once after all testing has been completed and no later than four weeks after the testing period has concluded Offeror(s) will submit a final report for the task order at the end of the award performance period to the CDC Project Officer at vsm8@cdc.gov
A four week lead time beyond the period of testing will be allowed for final report submission so that data collected at the end of the testing period can be incorporated in the final report.
| N/A | Invoicing | monthly | Offeror(s) will invoice their work under this contract monthly by submitting their invoices electronically to the CDC at fmoapinv@cdc.gov and copying the CDC Project Officer at vsm8@cdc.gov | Note: If offeror(s) are performing work under multiple task areas during one month, they may combine multiple task areas in one invoice as long as the work performed is distinguishable between task areas. |
| N/A | Status Updates and Meetings | upon award, bi-weekly, and upon request | Offeror(s) will update CDC regularly and respond to inquiries as requested. | Offeror(s) will be responsive to CDC requests for status updates and questions, especially given the importance of this work in addressing a public health emergency. |
Offeror(s) will include the CDC contract number in the body of all emails, reports, and meeting agendas for future tracking purposes.
| Task Area 3: Request for Reflexive COVID-19 Quantitative IgG Testing | ||||
| 3.1 | Reflexive Specimen Testing | begins 1.5 mos post-award | CDC estimates 1,600 specimens every two weeks requiring quantitative IgG testing, possibly spread among multiple offerors. | This testing will include quantitative IgG assays for for seropositive specimens identified qualitatively in task area 1.1. Tests (with specific test names) will be selected from offeror(s) proposals during the task order award. The required sample matrix and sample volume should be specified for each offered test name. |
| 3.2 | Draft Data Report | 1 and 2 weeks after reflexive testing begins | Offeror(s) will provide a sample draft data report electronically to the CDC Project Officer at vsm8@cdc.gov one week post award and schedule a meeting for review two weeks post award. | Data reports will include a 1-2 page cover letter stating a summary of findings, the CDC contract number, the tests run (with specific test names that are traceable to the task order test protocols offered), the total number of specimens tested, the total number of seropositive specimens identified, any items of note such as trends, corrective actions, or other anomalies, and be signed by the laboratory signatory. |
Data reports will include a locked Excel file, an unlocked Excel file, and a .CSV file type.
The data reports will include at a minimum: the test run date, the test name, any lab comments of note, test result(s), the units of measurement, test limits of detection, the remaining sample volume available for reflexive testing, and a column indicating seropositivity. Based on availability of metadata, the report will also include at a sample level: Patient age (years), Gender, Race and ethnicity (if available), Geographic location (residence 5-digit zip code), Provider zip code if residence not available, ICD10 diagnosis associated with the original laboratory test, Results (including collection date) of any previous COVID-19 testing on the same patient, Specimen collection date, Information on if the specimen came from an outpatient or inpatient facility (if available), Unique patient identifier to allow for deduplication of sample results from the same patient
| 3.3 | Data Reporting | every 2 weeks after reflexive testing begins | Offeror(s) will provide a data report electronically to the CDC Project Officer at vsm8@cdc.gov for every two weeks of testing post award. | |
| 3.4 | Draft Final Report and Review Meeting | once four weeks prior to end of performance period | Offeror(s) will submit a sample draft of the final report for the task order four weeks prior to the end of the award performance period to the CDC Project Officer at vsm8@cdc.gov | The final report will include at a minimum: a summary of work performed (total number of specimens analyzed, total number of specimens seropositive, and those totals broken out by each two-week surveillance period). |
The report appendices of the report should include at a minimum: each data report, shipping manifests (if applicable), test protocols, meeting agendas, and invoices.
3.5 Final Report once after all testing has been completed and no later than four weeks after the testing period has concluded Offeror(s) will submit a final report for the task order at the end of the award performance period to the CDC Project Officer at vsm8@cdc.gov
A four week lead time beyond the period of testing will be allowed for final report submission so that data collected at the end of the testing period can be incorporated in the final report.
| N/A | Invoicing | monthly | Offeror(s) will invoice their work under this contract monthly by submitting their invoices electronically to the CDC at fmoapinv@cdc.gov and copying the CDC Project Officer at vsm8@cdc.gov | Note: If offeror(s) are performing work under multiple task areas during one month, they may combine multiple task areas in one invoice as long as the work performed is distinguishable between task areas. |
| N/A | Status Updates and Meetings | upon award, bi-weekly, and upon request | Offeror(s) will update CDC regularly and respond to inquiries as requested. | Offeror(s) will be responsive to CDC requests for status updates and questions, especially given the importance of this work in addressing a public health emergency. |
Offeror(s) will include the CDC contract number in the body of all emails, reports, and meeting agendas for future tracking purposes.
File details come from the government source that posted it. Updated .